Hyper‐progressive disease after immune checkpoint inhibitor in SMARCA4‐deficient small‐cell lung carcinoma

Hyper‐progressive disease after immune checkpoint inhibitor in SMARCA4‐deficient small‐cell lung carcinoma

Abstract SMARCA4 (switch/sucrose non‐fermentable‐related, matrix‐associated, actin‐dependent regulator of chromatin, subfamily A, member 4)‐deficient thoracic tumours have shown poor prognosis in clinical settings. Although the optimal treatment for SMARCA4‐deficient thoracic tumours remains unclear...

Full description

Bibliographic Details
Main Authors: Yosuke Chiba, Toshinori Kawanami, Kei Yamasaki, Keigo Uchimura, Atsuji Matsuyama, Kazuhiro Yatera
Format: Article
Language:English
Published: Wiley 2020-11-01
Series:Respirology Case Reports
Subjects:
Hyper‐progressive disease
lung cancer
nivolumab
SMARCA4‐deficient small‐cell lung carcinoma
Online Access:https://doi.org/10.1002/rcr2.667

Internet

https://doi.org/10.1002/rcr2.667

Similar Items